Halozyme initiates Phase Ib/II oncology combination trial

US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news